Showing results (271-280 of 458) with videos related to
Sort By:
Pageof 46
Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment managementHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.Gynecologic Oncology|January 17, 2021
The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnosesPhilip E Castle, Alexander Locke, Ana I Tergas, et al.Infectious Agents and Cancer|November 1, 2011
HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancerRosemary E Zuna, Erin Tuller, Nicolas Wentzensen, et al.Eclinicalmedicine|October 3, 2022
Diagnostic accuracy of cervical cancer screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) among women living with HIV: A systematic review and meta-analysisHelen Kelly, Iman Jaafar, Michael Chung, et al.Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positiveHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 yearsHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.Cancer Cytopathology|April 4, 2020
Racial differences in HPV type 16 prevalence in women with ASCUS of the uterine cervixCarolann Risley, Megan A Clarke, Kim R Geisinger, et al.Journal of Clinical Microbiology|January 2, 2025
Validation of a simplified HPV genotyping assay designed for cervical screening in low-resource settingsKanan T Desai, Kayode O Ajenifuja, Clement A Adepiti, et al.International Journal of Cancer|August 9, 2011
Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatmentAimée R Kreimer, Mark Schiffman, Rolando Herrero, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 20, 2004
Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa RicaRaphael P Viscidi, Mark Schiffman, Allan Hildesheim, et al.Pageof 46